Concepts (147)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hearing Loss | 9 | 2023 | 45 | 1.850 |
Why?
|
| HIV Infections | 14 | 2023 | 913 | 1.180 |
Why?
|
| Nutrition Surveys | 5 | 2016 | 129 | 0.930 |
Why?
|
| Health Surveys | 3 | 2016 | 298 | 0.860 |
Why?
|
| Infectious Disease Transmission, Vertical | 6 | 2023 | 71 | 0.540 |
Why?
|
| Pregnancy Complications, Infectious | 5 | 2023 | 60 | 0.530 |
Why?
|
| Olfaction Disorders | 1 | 2016 | 11 | 0.520 |
Why?
|
| Prenatal Exposure Delayed Effects | 4 | 2020 | 151 | 0.430 |
Why?
|
| Auditory Threshold | 2 | 2015 | 26 | 0.420 |
Why?
|
| Presbycusis | 1 | 2012 | 6 | 0.400 |
Why?
|
| Acquired Immunodeficiency Syndrome | 2 | 2023 | 138 | 0.390 |
Why?
|
| Otoacoustic Emissions, Spontaneous | 3 | 2018 | 5 | 0.390 |
Why?
|
| Anti-Retroviral Agents | 4 | 2023 | 73 | 0.340 |
Why?
|
| Hearing | 4 | 2023 | 30 | 0.340 |
Why?
|
| Sensation Disorders | 3 | 2016 | 21 | 0.340 |
Why?
|
| Anti-HIV Agents | 2 | 2023 | 153 | 0.320 |
Why?
|
| Hearing Loss, Sensorineural | 3 | 2020 | 47 | 0.320 |
Why?
|
| Prevalence | 10 | 2019 | 1252 | 0.280 |
Why?
|
| Speech Perception | 2 | 2020 | 79 | 0.270 |
Why?
|
| Female | 27 | 2023 | 30705 | 0.260 |
Why?
|
| Pregnancy | 8 | 2023 | 2202 | 0.250 |
Why?
|
| Language Development Disorders | 2 | 2018 | 26 | 0.250 |
Why?
|
| Child | 10 | 2023 | 4174 | 0.240 |
Why?
|
| Postural Balance | 3 | 2016 | 60 | 0.230 |
Why?
|
| Language Disorders | 2 | 2016 | 24 | 0.230 |
Why?
|
| Hearing Disorders | 3 | 2015 | 7 | 0.230 |
Why?
|
| Vision Disorders | 3 | 2015 | 59 | 0.220 |
Why?
|
| United States | 11 | 2019 | 7390 | 0.200 |
Why?
|
| Male | 22 | 2020 | 27739 | 0.190 |
Why?
|
| Humans | 30 | 2023 | 59360 | 0.190 |
Why?
|
| Aged | 13 | 2022 | 13416 | 0.190 |
Why?
|
| Caloric Tests | 1 | 2020 | 1 | 0.170 |
Why?
|
| Ocular Motility Disorders | 1 | 2020 | 2 | 0.170 |
Why?
|
| Vestibular Evoked Myogenic Potentials | 1 | 2020 | 3 | 0.170 |
Why?
|
| Vestibular Diseases | 1 | 2020 | 9 | 0.170 |
Why?
|
| Infant | 4 | 2018 | 1486 | 0.170 |
Why?
|
| Adult | 13 | 2023 | 15669 | 0.170 |
Why?
|
| Noise | 1 | 2020 | 33 | 0.160 |
Why?
|
| HIV Seronegativity | 2 | 2019 | 18 | 0.160 |
Why?
|
| Risk Factors | 11 | 2018 | 4984 | 0.160 |
Why?
|
| Cytomegalovirus Infections | 1 | 2019 | 66 | 0.160 |
Why?
|
| Evoked Potentials, Auditory, Brain Stem | 1 | 2018 | 8 | 0.150 |
Why?
|
| Japan | 1 | 2018 | 51 | 0.150 |
Why?
|
| Smoke | 1 | 2018 | 23 | 0.150 |
Why?
|
| Population Surveillance | 1 | 2018 | 194 | 0.140 |
Why?
|
| Middle Aged | 10 | 2022 | 16317 | 0.130 |
Why?
|
| Audiometry, Speech | 1 | 2016 | 5 | 0.130 |
Why?
|
| Adolescent | 9 | 2023 | 5824 | 0.130 |
Why?
|
| Cohort Studies | 5 | 2023 | 2374 | 0.130 |
Why?
|
| Child, Preschool | 5 | 2023 | 1782 | 0.130 |
Why?
|
| HIV | 2 | 2018 | 68 | 0.130 |
Why?
|
| Dizziness | 1 | 2016 | 16 | 0.130 |
Why?
|
| Vertigo | 1 | 2016 | 17 | 0.130 |
Why?
|
| Cognitive Dysfunction | 1 | 2020 | 309 | 0.130 |
Why?
|
| Urban Health | 1 | 2015 | 40 | 0.120 |
Why?
|
| Correction of Hearing Impairment | 1 | 2015 | 2 | 0.120 |
Why?
|
| Arthritis | 1 | 2015 | 49 | 0.120 |
Why?
|
| Hearing Loss, High-Frequency | 1 | 2015 | 3 | 0.120 |
Why?
|
| Aged, 80 and over | 5 | 2018 | 5128 | 0.120 |
Why?
|
| Hearing Aids | 1 | 2015 | 4 | 0.120 |
Why?
|
| HIV Seropositivity | 1 | 2015 | 82 | 0.120 |
Why?
|
| Prospective Studies | 6 | 2018 | 3067 | 0.110 |
Why?
|
| Cochlea | 1 | 2014 | 22 | 0.110 |
Why?
|
| Activities of Daily Living | 1 | 2015 | 289 | 0.110 |
Why?
|
| Vision, Ocular | 1 | 2013 | 18 | 0.110 |
Why?
|
| Young Adult | 5 | 2023 | 4267 | 0.100 |
Why?
|
| Language Tests | 1 | 2012 | 39 | 0.100 |
Why?
|
| Sex Factors | 4 | 2018 | 935 | 0.090 |
Why?
|
| Sex Distribution | 1 | 2012 | 244 | 0.090 |
Why?
|
| Age Distribution | 1 | 2012 | 249 | 0.090 |
Why?
|
| Audiometry, Pure-Tone | 3 | 2015 | 26 | 0.090 |
Why?
|
| Case-Control Studies | 3 | 2020 | 1051 | 0.090 |
Why?
|
| Diabetes Complications | 1 | 2011 | 100 | 0.090 |
Why?
|
| Diabetes Mellitus | 2 | 2015 | 515 | 0.090 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2010 | 26 | 0.080 |
Why?
|
| Regression Analysis | 3 | 2016 | 485 | 0.080 |
Why?
|
| Age Factors | 4 | 2018 | 1504 | 0.080 |
Why?
|
| Iceland | 3 | 2015 | 8 | 0.080 |
Why?
|
| Pilot Projects | 2 | 2023 | 914 | 0.070 |
Why?
|
| Retrospective Studies | 2 | 2018 | 6071 | 0.070 |
Why?
|
| Cross-Sectional Studies | 3 | 2023 | 2373 | 0.070 |
Why?
|
| Geriatrics | 1 | 2007 | 41 | 0.070 |
Why?
|
| Disease Susceptibility | 1 | 2007 | 157 | 0.070 |
Why?
|
| Aging | 2 | 2015 | 710 | 0.070 |
Why?
|
| Risk Assessment | 2 | 2018 | 1921 | 0.070 |
Why?
|
| Environment | 1 | 2007 | 119 | 0.070 |
Why?
|
| Puerto Rico | 2 | 2019 | 134 | 0.060 |
Why?
|
| Genotype | 1 | 2007 | 617 | 0.060 |
Why?
|
| Genetic Variation | 1 | 2007 | 357 | 0.060 |
Why?
|
| Maternal Exposure | 1 | 2004 | 39 | 0.060 |
Why?
|
| Polychlorinated Biphenyls | 1 | 2004 | 39 | 0.060 |
Why?
|
| Cognition | 2 | 2020 | 455 | 0.060 |
Why?
|
| Environmental Pollutants | 1 | 2004 | 91 | 0.050 |
Why?
|
| Phenotype | 1 | 2007 | 1137 | 0.050 |
Why?
|
| Maternal Age | 1 | 2003 | 32 | 0.050 |
Why?
|
| Beds | 1 | 2003 | 10 | 0.050 |
Why?
|
| Longitudinal Studies | 2 | 2016 | 1189 | 0.050 |
Why?
|
| Mother-Child Relations | 1 | 2003 | 43 | 0.050 |
Why?
|
| Nonlinear Dynamics | 1 | 2022 | 24 | 0.050 |
Why?
|
| Income | 1 | 2003 | 156 | 0.050 |
Why?
|
| Birth Weight | 2 | 2016 | 81 | 0.040 |
Why?
|
| Vestibular Function Tests | 1 | 2020 | 4 | 0.040 |
Why?
|
| Sleep | 1 | 2003 | 215 | 0.040 |
Why?
|
| Signal-To-Noise Ratio | 1 | 2020 | 55 | 0.040 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2020 | 93 | 0.040 |
Why?
|
| Severity of Illness Index | 2 | 2016 | 1479 | 0.040 |
Why?
|
| Data Collection | 2 | 2016 | 371 | 0.040 |
Why?
|
| Audiometry | 2 | 2012 | 17 | 0.040 |
Why?
|
| Cytomegalovirus | 1 | 2019 | 90 | 0.040 |
Why?
|
| Surveys and Questionnaires | 2 | 2022 | 2513 | 0.040 |
Why?
|
| Behavioral Risk Factor Surveillance System | 1 | 2018 | 42 | 0.040 |
Why?
|
| Speech | 1 | 2018 | 62 | 0.040 |
Why?
|
| Central America | 1 | 2015 | 2 | 0.030 |
Why?
|
| West Indies | 1 | 2015 | 6 | 0.030 |
Why?
|
| South America | 1 | 2015 | 23 | 0.030 |
Why?
|
| Mexico | 1 | 2015 | 36 | 0.030 |
Why?
|
| Social Class | 1 | 2016 | 122 | 0.030 |
Why?
|
| Diagnostic Self Evaluation | 1 | 2015 | 23 | 0.030 |
Why?
|
| Neuropsychological Tests | 1 | 2016 | 371 | 0.030 |
Why?
|
| Psychometrics | 1 | 2016 | 362 | 0.030 |
Why?
|
| Developmental Disabilities | 1 | 2016 | 108 | 0.030 |
Why?
|
| Disability Evaluation | 1 | 2015 | 199 | 0.030 |
Why?
|
| Infant, Newborn | 1 | 2018 | 1283 | 0.030 |
Why?
|
| Walking | 1 | 2016 | 228 | 0.030 |
Why?
|
| Maternal-Fetal Exchange | 1 | 2013 | 28 | 0.030 |
Why?
|
| Osteoarthritis | 1 | 2015 | 131 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2015 | 745 | 0.030 |
Why?
|
| Socioeconomic Factors | 1 | 2015 | 741 | 0.030 |
Why?
|
| Cause of Death | 1 | 2013 | 210 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2013 | 396 | 0.020 |
Why?
|
| Motor Activity | 1 | 2015 | 333 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2013 | 674 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2014 | 902 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2012 | 589 | 0.020 |
Why?
|
| Logistic Models | 1 | 2012 | 1232 | 0.020 |
Why?
|
| Health Status Indicators | 1 | 2007 | 92 | 0.020 |
Why?
|
| Body Composition | 1 | 2007 | 146 | 0.020 |
Why?
|
| Osteoporosis | 1 | 2007 | 102 | 0.020 |
Why?
|
| Time Factors | 1 | 2013 | 3617 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2016 | 5284 | 0.020 |
Why?
|
| Body Height | 1 | 2004 | 68 | 0.010 |
Why?
|
| Chronic Disease | 1 | 2007 | 716 | 0.010 |
Why?
|
| Dementia | 1 | 2007 | 248 | 0.010 |
Why?
|
| Confidence Intervals | 1 | 2003 | 241 | 0.010 |
Why?
|
| Educational Status | 1 | 2003 | 264 | 0.010 |
Why?
|
| Cardiovascular Diseases | 1 | 2007 | 788 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2004 | 2337 | 0.010 |
Why?
|